Találati lista | Tudóstér

001-es BibID:	BIBFORM132955
Első szerző:	Homoródi Nóra (kardiológus)
Cím:	Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction / Homoródi Nóra, Varga Éva, Szabó Zoltán, Sztanek Ferenc, Harangi Mariann
Dátum:	2025
ISSN:	2227-9059
Megjegyzések:	Novel antidiabetic drugs introduced in the last decade have not only revolutionized the treatment of type 2 diabetes mellitus but have also changed our cardiovascular risk reduction strategy. Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of atherosclerotic diseases primarily through their complex anti-atherosclerotic effect due to their endothelial function-improving, anti-inflammatory, anti-thrombotic, and plaque-stabilizing effects. Sodium?glucose cotransporter 2 (SGLT2) inhibitors, on the other hand, have a favorable cardiovascular effect, mainly by increasing sodium excretion, reducing plasma volume, enhancing the use of ketone bodies as metabolic substrates in heart and kidney tissues, and reducing oxidative stress and uric acid serum levels. However, when using these two groups of drugs, important questions arise. What criteria should be used to decide on the administration of one or the other class of drugs? Which group of agents can be used more effectively to reduce our patients' cardiovascular risk? What are the possible adverse effects? What can be gained by combining the two drugs? Our objective was to provide a current literature-based and comparative summary on the mechanisms of action, cardiovascular-risk-reducing efficacy, and safety profiles of these two drug classes, with an emphasis on identifying key factors influencing everyday clinical decision-making.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk glucagon-like peptide-1 receptor inhibitors sodium-glucose transport protein 2 inhibitors cardiovascular diseases atherosclerosis type 2 diabetes mellitus therapeutic inertia adverse effects personalized treatment
Megjelenés:	Biomedicines. - 13 : 11 (2025), p. 1-24. -
További szerzők:	Varga Éva (1982-) (belgyógyász) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Sztanek Ferenc (1982-) (orvos) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	K142273 OTKA TKP2021-EGA-18 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM117400
035-os BibID:	(WoS)001130724100001 (Scopus)85180481804
Első szerző:	Nagy Attila Csaba (megelőző orvostan és népegészségtan szakorvos, epidemiológus)
Cím:	Enalapril Is Superior to Lisinopril in Improving Endothelial Function without a Difference in Blood-Pressure-Lowering Effects in Newly Diagnosed Hypertensives / Attila Nagy, Réka Májer, Judit Boczán, Sándor Sipka Jr., Attila Szabó, Enikő Edit Enyedi, Ottó Tatai, Miklós Fagyas, Zoltán Papp, László Csiba, Attila Tóth
Dátum:	2023
ISSN:	2227-9059
Megjegyzések:	Angiotensin-converting enzyme (ACE) inhibitors are the primarily chosen drugs to treat various cardiovascular diseases, such as hypertension. Although the most recent guidelines do not differentiate among the various ACE inhibitory drugs, there are substantial pharmacological differences. Goal: Here, we tested if lipophilicity affects the efficacy of ACE inhibitory drugs when used as the first therapy in newly identified hypertensives in a prospective study. Methods: We tested the differences in the cardiovascular efficacy of the hydrophilic lisinopril (8.3 +/- 3.0 mg/day) and the lipophilic enalapril (5.5 +/- 2.3 mg/day) (n = 59 patients). The cardiovascular parameters were determined using sonography (flow-mediated dilation (FMD) in the brachial artery, intima-media thickness of the carotid artery), 24 h ambulatory blood pressure monitoring (peripheral arterial blood pressure), and arteriography (aortic blood pressure, augmentation index, and pulse wave velocity) before and after the initiation of ACE inhibitor therapy. Results: Both enalapril and lisinopril decreased blood pressure. However, lisinopril failed to improve arterial endothelial function (lack of effects on FMD) when compared to enalapril. Enalapril-mediated improved arterial endothelial function (FMD) positively correlated with its blood-pressure-lowering effect. In contrast, there was no correlation between the decrease in systolic blood pressure and FMD in the case of lisinopril treatment. Conclusion: The blood-pressure-lowering effects of ACE inhibitor drugs are independent of their lipophilicity. In contrast, the effects of ACE inhibition on arterial endothelial function are associated with lipophilicity: the hydrophilic lisinopril was unable to improve, while the lipophilic enalapril significantly improved endothelial function. Moreover, the effects on blood pressure and endothelial function did not correlate in lisinopril-treated patients, suggesting divergent mechanisms in the regulation of blood pressure and endothelial function upon ACE inhibitory treatment.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Angiotensin converting enzyme (ACE) ACE inhibitor lisinopril enalapril clinical study endothelial function hypertension carotis IMT FMD
Megjelenés:	Biomedicines. - 11 : 12 (2023), p. 1-13. -
További szerzők:	Majer Réka (1988-) (egészségpszichológus) Boczán Judit (1972-) (neurológus) Sipka Sándor ifj. (1980-) (orvos) Szabó Attila Ádám (1996-) (orvos) Enyedi Enikő Edit (1995-) (orvosi laboratóriumi analitikus) Tatai Ottó (2003-) (orvostanhallgató) Fagyas Miklós (1984-) (orvos) Papp Zoltán (1965-) (kardiológus, élettanász) Csiba László (1952-) (neurológus, pszichiáter) Tóth Attila (kardiológus)
Pályázati támogatás:	POST-COVID2021-16 Egyéb POST-COVID2021-33 Egyéb NKM2022-30 Egyéb K132623 Egyéb K147243 Egyéb TKP2021-EGA-19 Egyéb TKP2021- EGA-20 Egyéb TKP2020-NKA-04 Egyéb BO/00069/21/5 Egyéb ÚNKP-23-5-DE-482 ÚNKP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: